[Modern aspects of shock treatment].
D000305:Adrenal Cortex Hormones / Q000494:pharmacology / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000804:Angiotensin II / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002021:Buffers / Q000187:drug effects / Q000627:therapeutic use; D002301:Cardiac Glycosides / Q000494:pharmacology / Q000627:therapeutic use; D002395:Catecholamines / Q000494:pharmacology / Q000627:therapeutic use; D004232:Diuretics / Q000494:pharmacology / Q000627:therapeutic use; D004573:Electrolytes / Q000494:pharmacology / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010952:Plasma Substitutes / Q000494:pharmacology / Q000627:therapeutic use; D011817:Rabbits; D051381:Rats; D012769:Shock / Q000188:drug therapy / Q000628:therapy*; D013565:Sympatholytics / Q000494:pharmacology / Q000627:therapeutic use; D065227:Transfusion Reaction; D014667:Vasopressins / Q000494:pharmacology / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000700:Analgesics; D000900:Anti-Bacterial Agents; D002021:Buffers; D002301:Cardiac Glycosides; D002395:Catecholamines; D004232:Diuretics; D004573:Electrolytes; D005343:Fibrinolytic Agents; D010952:Plasma Substitutes; D013565:Sympatholytics; D014667:Vasopressins; D000804:Angiotensin II
Moderne Aspekte der Schockbehandlung.